Please login to the form below

Not currently logged in
Email:
Password:

SHP465

This page shows the latest SHP465 news and features for those working in and with pharma, biotech and healthcare.

Shire claims FDA approval for slow-cooked ADHD drug

Shire claims FDA approval for slow-cooked ADHD drug

Formerly known as SHP465, Mydayis has been approved to treat ADHD in children aged over 13 and adults, as in younger patients it has higher rates of adverse reaction such as

Latest news

  • Shire launches long-acting ADHD drug Intuniv in UK Shire launches long-acting ADHD drug Intuniv in UK

    While Intuniv remains an important ADHD product for Shire, the company's main near-term ambition in the category is securing approval for SHP465, a mixed amphetamine salt product that it

  • Shire pitching at adult ADHD product launch in 2017 Shire pitching at adult ADHD product launch in 2017

    Shire wants to develop a drug called SHP465 (triple-bead mixed amphetamine salts) for adult ADHD, but to satisfy the FDA will have to first carry out a trial of the ... SHP465 will provide 16 hours cover from a single tablet, extending from the morning

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics